{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:02:12Z","timestamp":1777928532314,"version":"3.51.4"},"reference-count":21,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Allergy, Immunology, and Pulmonology"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Evidence has demonstrated that adding intermittent inhaled corticosteroids (ICS) to treatment with short-acting b2-agonists (SABAs) in children 5 years of age and younger who experience intermittent viral-induced wheezing (VIW) reduces the risk of severe exacerbations. However, there is concern about whether the extra benefit offered by this drug outweighs the additional cost. This study aimed to evaluate the cost-effectiveness of intermittent ICS in children 5 years of age and younger who experience intermittent VIW.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We constructed a probabilistic Markov model to estimate the cost and quality-adjusted life-years (QALYs) of intermittent ICS compared with SABA reliever therapy in preschoolers with viral-triggered wheezing in Colombia. Multiple sensitivity analyses were conducted. Cost-effectiveness was evaluated at a willingness-to-pay value of $5,180.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In an analysis of the Markov cohort model, we estimated a gain of 0.2 QALYs per patient per year on intermittent ICS compared with SABA and a reduction of cost per patient of USD $37 per year. This position of dominance negated the need to calculate an incremental cost-effectiveness ratio. Deterministic and probabilistic sensitivity analyses, our base case results were robust to variations of all assumptions and parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Adding intermittent ICS to treatment with SABAs in children 5 years of age and younger who experience intermittent VIW was found to be cost effective. These results could improve the use of health care resources, especially in settings with limited economic resources.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/ped.2021.0143","type":"journal-article","created":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T16:54:28Z","timestamp":1648054468000},"page":"36-42","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":11,"title":["Cost Utility of Intermittent Inhaled Corticosteroids in Preschoolers with Viral-Triggered Wheeze"],"prefix":"10.1177","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2404-6612","authenticated-orcid":false,"given":"Jefferson Antonio","family":"Buend\u00eda","sequence":"first","affiliation":[{"name":"Research Group in Pharmacology and Toxicology \u201cINFARTO,\u201d Department of Pharmacology and Toxicology, University of Antioquia, Medell\u00edn, Colombia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Guerrero Pati\u00f1o","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hospital Infantil Concejo de Medell\u00edn, Medell\u00edn, Colombia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Esteban","family":"Giraldo Ram\u00edrez","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hospital Infantil Concejo de Medell\u00edn, Medell\u00edn, Colombia."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,3,21]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2013.00391"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.07.011"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199501193320301"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2007.01394.x"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.aller.2019.06.015"},{"key":"e_1_3_4_7_2","first-page":"548","article-title":"The public health implications of asthma","volume":"83","author":"Bousquet J","year":"2005","unstructured":"Bousquet J, , Bousquet PJ, , Godard P, et al. The public health implications of asthma. Bull World Health Organ, 2005; 83:548\u2013554.","journal-title":"Bull World Health Organ"},{"key":"e_1_3_4_8_2","unstructured":"Asthma GIf. Global Strategy for Ashtma Management and Prevention 2021. Available from: https:\/\/ginasthma.org\/."},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-4496"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/heapol\/czab146"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.3109\/02770903.2013.767909"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.02.010"},{"key":"e_1_3_4_13_2","first-page":"CD013518","article-title":"Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma","volume":"5","author":"Crossingham I","year":"2021","unstructured":"Crossingham I, , Turner S, , Ramakrishnan S, et al. Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma. Cochrane Database Syst Rev, 2021; 5:CD013518.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00701-2020"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.202011-1386OC"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.04.016"},{"key":"e_1_3_4_17_2","unstructured":"(DANE) DNdE. Archivo nacional de datos 2019. Available from: https:\/\/sitios.dane.gov.co\/anda-index\/."},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-12-17"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.23073"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2008.29.3147"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g3009"},{"key":"e_1_3_4_22_2","first-page":"CD009878","article-title":"Inhaled corticosteroids in children with persistent asthma: dose-response effects on growth","volume":"7","author":"Pruteanu AI","year":"2014","unstructured":"Pruteanu AI, , Chauhan BF, , Zhang L, et al. Inhaled corticosteroids in children with persistent asthma: dose-response effects on growth. Cochrane Database Syst Rev, 2014; 7:CD009878.","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Pediatric Allergy, Immunology, and Pulmonology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/ped.2021.0143","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/ped.2021.0143","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/ped.2021.0143","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:15:26Z","timestamp":1777677326000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/ped.2021.0143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1089\/ped.2021.0143"],"URL":"https:\/\/doi.org\/10.1089\/ped.2021.0143","relation":{},"ISSN":["2151-321X","2151-3228"],"issn-type":[{"value":"2151-321X","type":"print"},{"value":"2151-3228","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}